Physician profile
Thomas Lim
NPI 1790775682
$759.03
in general payments reported to CMS, 2019-2025
12 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.68 · 2022: $119 · 2023: $171 · 2024: $262 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.83 | 2024 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $119.02 | 2025 | |
| Glaxosmithkline, LLC. | $100.83 | 2022-2023 | Benlysta, Jesduvroq |
| Lilly USA, LLC | $62.03 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.59 | 2023-2024 | Jardiance |
| Vifor Pharma, INC. | $56.55 | 2022 | |
| Horizon Therapeutics Plc | $50.92 | 2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $46.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.48 | 2019-2024 | Lokelma |
| Novo Nordisk INC | $21.75 | 2023 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $20.57 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.